Emanuela Ricciotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5732066/publications.pdf

Version: 2024-02-01

50 papers

6,491 citations

185998
28
h-index

197535 49 g-index

50 all docs 50 docs citations

50 times ranked

11700 citing authors

#	Article	IF	CITATIONS
1	Prostaglandins and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 986-1000.	1.1	2,681
2	Understanding multicellular function and disease with human tissue-specific networks. Nature Genetics, 2015, 47, 569-576.	9.4	738
3	Fatty acid transport proteinÂ2 reprograms neutrophils in cancer. Nature, 2019, 569, 73-78.	13.7	440
4	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Journal of the American College of Cardiology, 2005, 45, 1295-1301.	1.2	252
5	Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects. Circulation, 2004, 109, 1468-1471.	1.6	224
6	Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice. Science Translational Medicine, 2012, 4, 132ra54.	5.8	194
7	Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14507-14512.	3.3	186
8	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 2016, 7, 32462-32477.	0.8	130
9	The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. Trends in Pharmacological Sciences, 2017, 38, 733-748.	4.0	125
10	Microsomal Prostaglandin E Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin Il–Induced Abdominal Aortic Aneurysm Formation. Circulation, 2008, 117, 1302-1309.	1.6	124
11	De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin. Circulation Research, 2006, 98, 593-595.	2.0	122
12	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. Journal of Clinical Investigation, 2017, 127, 2407-2417.	3.9	121
13	Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7548-7552.	3.3	107
14	The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity. Current Medical Research and Opinion, 2002, 18, 503-511.	0.9	82
15	Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans. Journal of Biological Chemistry, 2008, 283, 1179-1188.	1.6	81
16	Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. Pharmaceuticals, 2012, 5, 1346-1371.	1.7	64
17	A comparison of Illumina and Ion Torrent sequencing platforms in the context of differential gene expression. BMC Genomics, 2017, 18, 602.	1.2	57
18	Niacin and biosynthesis of PGD2 by platelet COX-1 in mice and humans. Journal of Clinical Investigation, 2012, 122, 1459-1468.	3.9	57

#	Article	IF	Citations
19	NSAID–Gut Microbiota Interactions. Frontiers in Pharmacology, 2020, 11, 1153.	1.6	56
20	Targeted Deletions of Cyclooxygenase-2 and Atherogenesis in Mice. Circulation, 2010, 121, 2654-2660.	1.6	55
21	Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochemical Pharmacology, 2010, 79, 974-981.	2.0	49
22	COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer. Oncogene, 2018, 37, 4735-4749.	2.6	48
23	Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6727-6732.	3.3	45
24	Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. British Journal of Pharmacology, 2003, 138, 634-641.	2.7	41
25	COX-2, the dominant source of prostacyclin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E183.	3.3	41
26	Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood, 2006, 107, 3572-3574.	0.6	36
27	A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. JCI Insight, 2016, 1, .	2.3	33
28	Effects of Celecoxib on Prostanoid Biosynthesis and Circulating Angiogenesis Proteins in Familial Adenomatous Polyposis. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 242-250.	1.3	31
29	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clinical Pharmacology and Therapeutics, 2006, 80, 115-125.	2.3	27
30	Lipocalin-Like Prostaglandin D Synthase but Not Hemopoietic Prostaglandin D Synthase Deletion Causes Hypertension and Accelerates Thrombogenesis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 425-432.	1.3	26
31	Aspirin in Hepatocellular Carcinoma. Cancer Research, 2021, 81, 3751-3761.	0.4	24
32	Comparative evaluation of RNA-Seq library preparation methods for strand-specificity and low input. Scientific Reports, 2019, 9, 13477.	1.6	22
33	NCX 4040, a Nitric Oxide-Donating Aspirin, Exerts Anti-Inflammatory Effects through Inhibition of lκB-α Degradation in Human Monocytes. Journal of Immunology, 2010, 184, 2140-2147.	0.4	20
34	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium–Induced Colitis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 416-426.	1.3	18
35	Aspirin in the Prevention of Cardiovascular Disease and Cancer. Annual Review of Medicine, 2021, 72, 473-495.	5.0	17
36	Myeloid Cell 5-Lipoxygenase Activating Protein Modulates the Response to Vascular Injury. Circulation Research, 2013, 112, 432-440.	2.0	14

#	Article	IF	CITATIONS
37	Functionalized Low-Density Lipoprotein Nanoparticles for in Vivo Enhancement of Atherosclerosis on Magnetic Resonance Images. Bioconjugate Chemistry, 2012, 23, 2313-2319.	1.8	13
38	Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. Circulation, 2018, 138, 2367-2378.	1.6	13
39	Prostaglandin regulation of T cell biology. Pharmacological Research, 2019, 149, 104456.	3.1	13
40	LDL-mimetic lipid nanoparticles prepared by surface KAT ligation for <i>in vivo</i> MRI of atherosclerosis. Chemical Science, 2020, 11, 11998-12008.	3.7	13
41	Druggable Prostanoid Pathway. Advances in Experimental Medicine and Biology, 2020, 1274, 29-54.	0.8	12
42	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Advances in Biological Regulation, 2021, 81, 100818.	1.4	10
43	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. Frontiers in Public Health, 2021, 9, 751451.	1.3	9
44	Modulation of Apoptotic Cell Death and Neuroprotective Effects of Glutathioneâ€"L-Dopa Codrug Against H2O2-Induced Cellular Toxicity. Antioxidants, 2019, 8, 319.	2.2	6
45	Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo. Frontiers in Pharmacology, 2020, 11, 374.	1.6	6
46	Distinct vascular genomic response of proton and gamma radiationâ€"A pilot investigation. PLoS ONE, 2019, 14, e0207503.	1.1	4
47	Anti-Migratory Effects of 4′-Geranyloxyferulic Acid on LPS-Stimulated U937 and HCT116 Cells via MMP-9 Down-Regulation: Involvement of ROS/ERK Signaling Pathway. Antioxidants, 2020, 9, 470.	2.2	2
48	Sex-dependent compensatory mechanisms preserve blood pressure homeostasis in prostacyclin receptor–deficient mice. Journal of Clinical Investigation, 2021, 131, .	3.9	1
49	Editorial: Eicosanoids in Cancer. Frontiers in Pharmacology, 2021, 12, 765214.	1.6	1
50	Systemic Eicosanoid and Cytokine Response to Niacin: Implications in HPS2-THRIVE Trial and Beyondâ€â^—. Journal of Clinical Lipidology, 2014, 8, 309-310.	0.6	0